Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia
Background: This study was designed to evaluate the comparison of insertion of levonorgestrel (LNG)-releasing intrauterine system versus oral medroxyprogesterone acetate on endometrial hyperplasia in a randomized controlled trial. Materials and Methods: A total of 60 women with the initial histopath...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
| Series: | Journal of Research in Medical Sciences |
| Subjects: | |
| Online Access: | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2014;volume=19;issue=8;spage=686;epage=690;aulast=Behnamfar |
| _version_ | 1818354997300035584 |
|---|---|
| author | Fariba Behnamfar Attaollah Ghahiri Marzieh Tavakoli |
| author_facet | Fariba Behnamfar Attaollah Ghahiri Marzieh Tavakoli |
| author_sort | Fariba Behnamfar |
| collection | DOAJ |
| description | Background: This study was designed to evaluate the comparison of insertion of levonorgestrel (LNG)-releasing intrauterine system versus oral medroxyprogesterone acetate on endometrial hyperplasia in a randomized controlled trial. Materials and Methods: A total of 60 women with the initial histopathological diagnosis of endometrial hyperplasia in two groups received LNG or medroxyprogesterone (10 mg/d orally) for 12 days a month for 3 months). Endometrial biopsy was obtained for all patients after 3 months of treatment. Response to treatment was defined based on the histopathology of the post treatment pipelle endometrial specimens in three categories of resolution, persistence and progression. Results: Treatment response rate in patients in the LNG group was 89.3% (25 of 28 patients), versus 70.4% (19 of 27 patients) in patients in the medroxyprogesterone group. The rate of persistence was 10.7% (3 of 28 patients) and 22.2% (6 of 27 patients) in LNG and medroxyprogesterone groups respectively. No progression of endometrial hyperplasia observed in any of the patients in LNG group, but progression of endometrial hyperplasia was observed in 7.4% (2 of 27 patients) in the medroxyprogesterone group. There was no statistically significant difference between groups regarding the response to treatment (P = 0.15). Side effects such as bloating, weight gain, fatigue and hair loss were comparable between the groups (P > 0.05). Hirsutism was significantly more in the medroxyprogesterone group than LNG group (P = 0.013). Conclusion: Results showed that the use of LNG for treating endometrial hyperplasia for 3 months was associated with high-treatment response rate and the low proportion of patients with progression compared to the use of medroxyprogesterone. |
| first_indexed | 2024-12-13T19:34:19Z |
| format | Article |
| id | doaj.art-5540677e71f14b2897782033fa8cf251 |
| institution | Directory Open Access Journal |
| issn | 1735-1995 1735-7136 |
| language | English |
| last_indexed | 2024-12-13T19:34:19Z |
| publishDate | 2014-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Research in Medical Sciences |
| spelling | doaj.art-5540677e71f14b2897782033fa8cf2512022-12-21T23:33:52ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362014-01-01198686690Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasiaFariba BehnamfarAttaollah GhahiriMarzieh TavakoliBackground: This study was designed to evaluate the comparison of insertion of levonorgestrel (LNG)-releasing intrauterine system versus oral medroxyprogesterone acetate on endometrial hyperplasia in a randomized controlled trial. Materials and Methods: A total of 60 women with the initial histopathological diagnosis of endometrial hyperplasia in two groups received LNG or medroxyprogesterone (10 mg/d orally) for 12 days a month for 3 months). Endometrial biopsy was obtained for all patients after 3 months of treatment. Response to treatment was defined based on the histopathology of the post treatment pipelle endometrial specimens in three categories of resolution, persistence and progression. Results: Treatment response rate in patients in the LNG group was 89.3% (25 of 28 patients), versus 70.4% (19 of 27 patients) in patients in the medroxyprogesterone group. The rate of persistence was 10.7% (3 of 28 patients) and 22.2% (6 of 27 patients) in LNG and medroxyprogesterone groups respectively. No progression of endometrial hyperplasia observed in any of the patients in LNG group, but progression of endometrial hyperplasia was observed in 7.4% (2 of 27 patients) in the medroxyprogesterone group. There was no statistically significant difference between groups regarding the response to treatment (P = 0.15). Side effects such as bloating, weight gain, fatigue and hair loss were comparable between the groups (P > 0.05). Hirsutism was significantly more in the medroxyprogesterone group than LNG group (P = 0.013). Conclusion: Results showed that the use of LNG for treating endometrial hyperplasia for 3 months was associated with high-treatment response rate and the low proportion of patients with progression compared to the use of medroxyprogesterone.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2014;volume=19;issue=8;spage=686;epage=690;aulast=BehnamfarEndometrial hyperplasialevonorgestrel-releasing intrauterine systemmedroxyprogesterone |
| spellingShingle | Fariba Behnamfar Attaollah Ghahiri Marzieh Tavakoli Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia Journal of Research in Medical Sciences Endometrial hyperplasia levonorgestrel-releasing intrauterine system medroxyprogesterone |
| title | Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia |
| title_full | Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia |
| title_fullStr | Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia |
| title_full_unstemmed | Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia |
| title_short | Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia |
| title_sort | levonorgestrel releasing intrauterine system mirena in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia |
| topic | Endometrial hyperplasia levonorgestrel-releasing intrauterine system medroxyprogesterone |
| url | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2014;volume=19;issue=8;spage=686;epage=690;aulast=Behnamfar |
| work_keys_str_mv | AT faribabehnamfar levonorgestrelreleasingintrauterinesystemmirenaincomparetomedroxyprogesteroneacetateasatherapyforendometrialhyperplasia AT attaollahghahiri levonorgestrelreleasingintrauterinesystemmirenaincomparetomedroxyprogesteroneacetateasatherapyforendometrialhyperplasia AT marziehtavakoli levonorgestrelreleasingintrauterinesystemmirenaincomparetomedroxyprogesteroneacetateasatherapyforendometrialhyperplasia |